…

Extracellular vesicles have moved from being regarded as cellular debris to being recognized as active participants in intercellular communication, and this shift in perspective has reshaped how researchers think about inflammatory disease in the digestive tract. The review by Wang and colleagues arrives at a moment when laboratories around the world are cataloguing the cargo of these vesicles in increasing detail, and their synthesis highlights how much of the recent evidence centers on colitis, the most intensively studied form of gastrointestinal inflammation. The authors organize their discussion around the idea that immune cells do not simply release soluble mediators such as cytokines and chemokines; they also package regulatory molecules into membrane-bound vesicles that can travel through tissue fluid and blood, survive enzymatic degradation, and deliver their contents to specific recipient cells. This packaging confers several advantages over free-floating signaling molecules. Proteins and nucleic acids enclosed within a lipid bilayer are protected from serum proteases and nucleases, the vesicle surface can display adhesion molecules that favor binding to particular cell types, and because the vesicles are endogenous structures, they generally do not provoke the kind of immune rejection that complicates synthetic drug delivery systems.

The biogenesis of extracellular vesicles is central to understanding why different vesicle populations behave so differently. Exosomes arise through the endosomal pathway: early endosomes mature into late endosomes, and inward budding of the limiting membrane generates intraluminal vesicles within multivesicular bodies. When these bodies fuse with the plasma membrane, their intraluminal vesicles are released as exosomes, typically in the small vesicle range below 200 nanometers. Ectosomes, by contrast, form by direct outward budding and shedding of the plasma membrane, a process that tends to produce larger vesicles. Migrasomes, a more recently described subtype, form on retraction fibers left behind by migrating cells, while apoptotic bodies are released as cells undergo programmed death and fragment. The authors note that the latest MISEV guidelines discourage overreliance on biogenesis-based nomenclature, since the origin of a given vesicle preparation is often uncertain, and instead recommend operational classifications based on physical characteristics such as size and density, on biochemical composition, or on the cell type and conditions from which the vesicles were obtained. This pragmatic approach matters for reproducibility, because studies that simply report isolating exosomes may actually be working with heterogeneous mixtures of vesicle subtypes.

Among the immune cell sources discussed, macrophages receive particularly detailed attention, reflecting their dual role in gastrointestinal inflammation. Classically activated M1 macrophages can drive tissue damage, and the review describes vesicles from these cells that promote colitis progression by activating the TLR4 signaling pathway in recipient cells. Other macrophage-derived vesicles carry microRNA-223, which suppresses the expression of TMIGD1, a protein involved in maintaining intestinal barrier integrity, thereby contributing to barrier dysfunction. A further example involves tumor necrosis factor carried on vesicles, which engages the TNFR2 receptor and the NF-κB pathway in recipient cells; the review describes this axis both as a mechanism that protects CD4-positive T cells from activation-induced cell death and as a trigger for glycolytic reprogramming and inflammatory activation in macrophages themselves. These findings illustrate a recurring theme: the same vesicle-associated signal can have context-dependent effects, protecting some cells while activating pro-inflammatory programs in others, depending on the recipient cell type and the state of the local microenvironment.

Vesicles from other immune populations add further layers to this regulatory network. The review describes vesicles carrying microRNA-21a-5p, which reduces E-cadherin expression and thereby activates group 2 innate lymphoid cells through the KLRG1/GATA-3 axis, linking epithelial adhesion molecule shedding to innate lymphoid cell activity. Vesicle proteins from M1 macrophages are also reported to influence T lymphocyte viability and proliferation. Although the excerpted evidence focuses on inflammatory bowel disease, the authors extend their discussion to inflammatory conditions in other segments of the digestive tract, emphasizing that immune cell-derived vesicles can act on epithelial cells directly as well as on other immune cells, creating feedback loops that can either amplify or resolve inflammation depending on the cargo involved.

The therapeutic implications of this work rest on two complementary strategies. The first is to use immune cell-derived vesicles as drug carriers. Because vesicles are naturally occurring nanoscale structures, they can cross biological barriers, protect their payload from degradation, and deliver cargo to cells with which their surface molecules have affinity. The authors highlight advances in biological nanotechnology that make it feasible to isolate, characterize, and modify vesicles for therapeutic purposes. The second strategy is to modify vesicles themselves to enhance their efficacy, and the review offers a classification of modification approaches based on fundamental principles, which the authors present as an intuitive framework for readers. Such modifications can, in principle, alter vesicle tropism, change cargo loading, or adjust surface signaling molecules to bias recipient cell responses toward resolution of inflammation rather than its perpetuation.

Several practical considerations temper the enthusiasm surrounding these approaches. Isolation and purification of vesicles from cell culture supernatants or body fluids remains technically challenging, and contamination with protein aggregates or lipoproteins can confound functional studies. Standardization of vesicle characterization, in line with the MISEV framework the authors cite, will be essential for comparing results across laboratories. Dosing presents another challenge, since vesicle preparations are heterogeneous and potency may vary with the state of the parent cells at the time of collection. The source of vesicles for clinical use also matters; vesicles derived from allogeneic immune cells may carry donor-specific molecules, while vesicles engineered from cell lines may not fully recapitulate the behavior of primary cell-derived vesicles. The review acknowledges that the mechanisms of vesicle formation are not yet fully understood, which limits the precision with which vesicle production can be controlled.

The rising incidence and prevalence of gastrointestinal inflammation noted by the authors underscores the clinical urgency of this research. Chronic inflammatory conditions of the digestive tract impose substantial burdens on patients and healthcare systems, and existing treatments, while helpful for many, do not achieve durable remission in all patients and can carry significant side effects. Immune cell-derived vesicles offer a potential avenue for more targeted intervention, one that works with, rather than against, endogenous signaling pathways. The functional network the authors map, connecting various immune cell types and their vesicle-mediated crosstalk with epithelial and other cells, provides a framework for identifying which vesicle populations might be most amenable to therapeutic manipulation.

Looking forward, the review points toward several research directions. Better characterization of vesicle cargo under different inflammatory conditions could yield biomarkers for disease activity or treatment response. Deeper understanding of how vesicles navigate the gastrointestinal environment, including the mucus layer, the epithelial barrier, and the microbiota, will be needed before vesicle-based therapies can be reliably delivered to target sites. And continued refinement of modification strategies, guided by the classification the authors propose, may eventually allow researchers to design vesicles with defined cargo and tropism, transforming a naturally occurring communication system into a controllable therapeutic platform for inflammatory diseases of the digestive tract.

Subject of Research: Novel perspective on immune cell regulation in gastrointestinal inflammation: the role of extracellular vesicles and therapeutic prospects

Article Title: Novel perspective on immune cell regulation in gastrointestinal inflammation: the role of extracellular vesicles and therapeutic prospects

Article References: Wang, J., Xu, J., Cui, Z., & Wu, J. (2026). Novel perspective on immune cell regulation in gastrointestinal inflammation: the role of extracellular vesicles and therapeutic prospects. Experimental Biology and Medicine, 251, Article 11114. https://doi.org/10.3389/ebm.2026.11114

Image Credits: AI Generated

DOI: 10.3389/ebm.2026.11114

Keywords: Novel, perspective, immune, cell, regulation, gastrointestinal, inflammation, role, extracellular, vesicles, therapeutic, prospects